156 related articles for article (PubMed ID: 33026750)
21. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
Göksu SS; Tatlı AM; Geredeli Ç; Atcı M; Besen AA; Mertsoylu H; Uysal M; Özdoğan M; Aydın SG; Bilici A; Karaağaç M; Artaç M; Kaplan MA; Ebinç S; Coşkun HŞ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):805-812. PubMed ID: 34312705
[TBL] [Abstract][Full Text] [Related]
22. Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance.
Takahashi H; Asaka J; Tairabune T; Ujiie H; Matsuura Y; Nihei S; Kimura T; Chiba T; Kudo K
J Clin Pharm Ther; 2021 Oct; 46(5):1404-1411. PubMed ID: 34145608
[TBL] [Abstract][Full Text] [Related]
23. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
24. Case of cetuximab-induced disseminated necrotic and maculopapular eruptions: Involvement of an epidermal growth factor receptor inhibitor with epidermal necrosis.
Namiki T; Omigawa C; Nojima K; Wakasa T; Tokoro S; Hanafusa T; Miura K; Yokozeki H
J Dermatol; 2018 Jan; 45(1):e3-e4. PubMed ID: 28971521
[No Abstract] [Full Text] [Related]
25. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
26. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
27. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
28. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
30. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
32. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
33. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
[TBL] [Abstract][Full Text] [Related]
34. Assessment of demodex presence in acne-like rash associated with cetuximab.
Aksu Arıca D; Ozturk Topcu T; Baykal Selçuk L; Yaylı S; Seyman U; Fidan E; Bahadır S; Kavgacı H
Cutan Ocul Toxicol; 2017 Sep; 36(3):220-223. PubMed ID: 27802779
[TBL] [Abstract][Full Text] [Related]
35. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
Xu Y; Gao Z; Hu R; Wang Y; Wang Y; Su Z; Zhang X; Yang J; Mei M; Ren Y; Li M; Zhou X
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697216
[TBL] [Abstract][Full Text] [Related]
36. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
37. Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab.
Roman J; Dissaux G; Gouillou M; Gobel Y; Potard G; Leclere JC; Conan-Charlet V; Gujral D; Abgral R; Guibourg B; Pradier O; Schick U
Target Oncol; 2017 Aug; 12(4):505-512. PubMed ID: 28580506
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
39. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
Rhee J; Oishi K; Garey J; Kim E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S101-6. PubMed ID: 16336749
[TBL] [Abstract][Full Text] [Related]
40. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.
Fujimura T; Lyu C; Tsukada A; Sato Y; Kambayashi Y; Aiba S
J Dermatol; 2019 May; 46(5):e177-e178. PubMed ID: 30353913
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
